Jacob Pitcovski

Prof. Jacob Pitcovski


Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Vaccine
Verified
Journal Article
Closed access
JPJacob Pitcovski
Jacob Pitcovski
BGBezalel Gutter
Bezalel Gutter
GGGilad Gallili
Gilad Gallili
MGMartin Goldway
Martin Goldway
BPBeny Perelman
Beny Perelman
AMAmnon Michael
Amnon Michael

11 June 2010 in Avian Pathology
Verified
Journal Article
Open access
DGDana Goldenberg
Dana Goldenberg
MPMetsada Pasmanik-Chor
Metsada Pasmanik-Chor
MPMichael Pirak
Michael Pirak
NKNava Kass
Nava Kass
ALAvishai Lublin
Avishai Lublin
JPJacob Pitcovski
Jacob Pitcovski
Avian reovirus (ARV) causes viral arthritis, tenosynovitis, liver infection and immunosuppression in birds. Live-attenuated and inactivated vaccines for ARV are available, but do not efficiently protect against recent variants. Sigma C, which mediates virus attachment to target cells, is the most variable protein in ARV. Antibodies to this protein neutralize viral infection. The purpose of the present study was to characterize sigma C in isolates of ARV from infected birds, as compared with the vaccine strain. Amino acids 27 to 293 of sigma C from 28 Israeli isolates were compared, classified and analysed using bioinformatics tools. Large variations were found among the isolates, and the vaccine strain was shown to differ from most of the studied strains, which could explain the failure of commonly used vaccinations in protecting birds against ARV infection. Based on sigma C protein sequences from all over the world, ARV can be divided into four groups. Isolates from all groups were found in the field simultaneously, possibly explaining the insufficient protection achieved by the vaccine strain, which is represented in one of the groups. The results point out the need and the difficulty in producing a wide-ranging vaccine. Several conserved regions among all reported ARV sigma C proteins were identified. These peptides were further studied for structural and functional properties, and for antigenic characterization. The results of this study shed light on peptide selection for a broad and efficient vaccine.

8 December 2014 in Immunology
Verified
Journal Article
Closed access
PDF file
TGTal Gefen
Tal Gefen
JVJacob Vaya
Jacob Vaya
SKSoliman Khatib
Soliman Khatib
IRIrena Rapoport
Irena Rapoport
MLMeital Lupo
Meital Lupo
JPJacob Pitcovski
Jacob Pitcovski

5 July 2018 in Avian Pathology
Verified
Journal Article
Closed access
ESEhud Shahar
Ehud Shahar
RHRuth Haddas
Ruth Haddas
DGDana Goldenberg
Dana Goldenberg
ALAvishai Lublin
Avishai Lublin
IBItai Bloch
Itai Bloch
JPJacob Pitcovski
Jacob Pitcovski
Newcastle disease virus (NDV) is a major cause of infectious mortality and morbidity in poultry worldwide. It is an enveloped virus with two outer-membrane proteins—haemagglutinin-neuraminidase (HN) and fusion protein (F)—that induce neutralizing antibodies. All NDV strains belong to one serotype. Yet, NDV vaccines, derived from genotype II, do not fully prevent infection or shedding of viruses from other genotypes. The aim of this study was to test if an updated vaccine is required. For this purpose, NDVs isolated from infected, albeit heavily vaccinated, flocks were genetically and immunologically characterized. Amino acid differences in F and HN protein sequences were identified between the vaccine strain and each of the isolates, some specifically at the neutralization sites. Whereas all tested isolates showed similar haemagglutination-inhibition (HI) titres, 100–100,000 times higher antibody-to-virus ratios were needed to neutralize viral propagation in embryos by the field isolates versus the vaccine strain. As a result, a model and an equation were developed to explain the phenomenon of escape in one-serotype viruses and to calculate the HI values needed for protection, depending on variation rate at key positions. In conclusion, to confer full protection against NDVs that differ from the vaccine strain at the neutralizing epitopes, very high levels of antibodies should be raised and maintained to compensate for the reduction in the number of effective epitopes; alternatively, an adjusted attenuated vaccine should be developed—a task made possible in the current era of reverse vaccinology.

1 June 2016 in Vaccine
Verified
Journal Article
Closed access
DGDana Goldenberg
Dana Goldenberg
ALAvishai Lublin
Avishai Lublin
EREzra Rosenbluth
Ezra Rosenbluth
EHE. Dan Heller
E. Dan Heller
JPJacob Pitcovski
Jacob Pitcovski

8 April 2008 in Avian Pathology
Verified
Journal Article
Closed access
DLD. Lazarus
D. Lazarus
MPM. Pasmanik-Chor
M. Pasmanik-Chor
BGB. Gutter
B. Gutter
GGG. Gallili
G. Gallili
MBM. Barbakov
M. Barbakov
JPJacob Pitcovski
Jacob Pitcovski
A very virulent strain of infectious bursal disease virus (IBDVks) was isolated from the bursae of Fabricius of IBDV-affected broiler chickens. Following 43 serial passages in specific pathogen-free embryonated eggs, an attenuated strain was established (IBDVmb). Dosages of IBDVmb in the range 10(2) to 10(4) embryo infective dose of 50% were found to be safe and protective for commercial chicks. Chickens vaccinated with live vaccine containing IBDVmb responded with precipitating and type-specific neutralizing antibodies, and were immune to subsequent challenge with a very virulent IBDV. IBDVmb has been used as an attenuated vaccine throughout the world since 1993. A comparison of the full sequences of the virulent and attenuated strains (IBDVks and IBDVmb, respectively) revealed seven nucleotides that were different, four of them leading to changes in the amino-acid sequence. Comparison of the protein sequence of these strains and published sequences of very virulent and attenuated phenotypes lead us to suggest that the novel difference responsible for virulence of the Israeli strains are: residue 272 (VP2, very conserved site) and residue 527 (VP4), both in segment A, and in segment B (VP1) residues 96 and 161 (both conserved). Our study strengthens the possibility that more than one protein is involved in IBDV attenuation. In all reports, including ours, virulence was reduced without affecting antigenicity of the neutralizing epitopes in VP2. This could have practical implications for attenuated-vaccine development.